Citi Turns Bearish on Moderna After 600% Stock Surge

Citi has told investors to sell Moderna shares after the stock gained more than 600%, arguing the rally has outrun the company's fundamentals.

The call rests on a straightforward gap: Moderna's revenue and profit forecasts do not justify the expectations baked into its share price, according to Citi's analysts. After a six-fold-plus run in the stock, the bank sees the risk skewed toward disappointment rather than further upside.

The downgrade lands on the mechanics of valuation. When a share price rises 600% or more, the market is pricing in years of aggressive growth in both revenue and earnings. Citi's analysts looked at what Moderna has actually guided for and concluded the numbers fall short of that premium. Their verdict is blunt: the hype exceeds what the forecasts support.

That is a notable reversal of sentiment toward a company whose equity has been among the most dramatic performers in the market. A 600% gain transforms the math for any holder — the price already reflects enormous success, and each additional percentage point requires new evidence to sustain it. Citi's position is that the evidence, in the form of Moderna's own revenue and profit projections, does not clear that bar.

For investors, the recommendation converts an abstract debate about valuation into a concrete instruction: take the gains. Citi's analysts attribute their sell rating directly to the mismatch between forecast financials and the market's embedded optimism, not to any dispute about the company's underlying technology or pipeline per se — the argument is about price.

The so-what for the broader market is equally direct. Momentum of this magnitude invites scrutiny, and when a major bank's research desk concludes that forecasts cannot carry the valuation, the burden of proof shifts to the company's next set of numbers. Moderna's future results will now be measured against a share price that, in Citi's assessment, already assumes more than the forecasts deliver.